TW457094B - Topical composition for enhancing lipid barrier synthesis - Google Patents
Topical composition for enhancing lipid barrier synthesis Download PDFInfo
- Publication number
- TW457094B TW457094B TW086113282A TW86113282A TW457094B TW 457094 B TW457094 B TW 457094B TW 086113282 A TW086113282 A TW 086113282A TW 86113282 A TW86113282 A TW 86113282A TW 457094 B TW457094 B TW 457094B
- Authority
- TW
- Taiwan
- Prior art keywords
- skin
- scope
- topical composition
- alcohol
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 150000002632 lipids Chemical class 0.000 title claims abstract description 39
- 230000004888 barrier function Effects 0.000 title claims abstract description 34
- 230000000699 topical effect Effects 0.000 title claims abstract description 23
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 5
- 230000002708 enhancing effect Effects 0.000 title abstract description 3
- 206010013786 Dry skin Diseases 0.000 claims abstract description 8
- 230000037336 dry skin Effects 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- 241000533293 Sesbania emerus Species 0.000 claims description 28
- 230000001965 increasing effect Effects 0.000 claims description 12
- BYXCFUMGEBZDDI-UHFFFAOYSA-N 1,3,7-trimethyluric acid Chemical compound CN1C(=O)N(C)C(=O)C2=C1NC(=O)N2C BYXCFUMGEBZDDI-UHFFFAOYSA-N 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 10
- -1 alcohol ester Chemical class 0.000 claims description 9
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 5
- 235000015170 shellfish Nutrition 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 229940049918 linoleate Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 1
- 229940096386 coconut alcohol Drugs 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- 229960002646 scopolamine Drugs 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 2
- DNJVYWXIDISQRD-UHFFFAOYSA-N Cafestol Natural products C1CC2(CC3(CO)O)CC3CCC2C2(C)C1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-UHFFFAOYSA-N 0.000 abstract 1
- JEKMKNDURXDJAD-UHFFFAOYSA-N Kahweol Natural products C1CC2(CC3(CO)O)CC3CCC2C2(C)C1C(C=CO1)=C1C=C2 JEKMKNDURXDJAD-UHFFFAOYSA-N 0.000 abstract 1
- DNJVYWXIDISQRD-JTSSGKSMSA-N cafestol Chemical compound C([C@H]1C[C@]2(C[C@@]1(CO)O)CC1)C[C@H]2[C@@]2(C)[C@H]1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-JTSSGKSMSA-N 0.000 abstract 1
- JEKMKNDURXDJAD-HWUKTEKMSA-N kahweol Chemical compound C([C@@H]1C[C@]2(C[C@@]1(CO)O)CC1)C[C@H]2[C@@]2(C)[C@H]1C(C=CO1)=C1C=C2 JEKMKNDURXDJAD-HWUKTEKMSA-N 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 50
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 210000000434 stratum corneum Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002079 cooperative effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DBERHVIZRVGDFO-UHFFFAOYSA-N Acetoxyacetone Chemical compound CC(=O)COC(C)=O DBERHVIZRVGDFO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- DVWJFTGEISXVSH-CWVFEVJCSA-N (1R,3S,5S,7Z,11R,12S,13Z,15Z,17Z,19Z,21R,23S,24R,25S)-21-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-12-ethyl-1,3,5,25-tetrahydroxy-11-methyl-9-oxo-10,27-dioxabicyclo[21.3.1]heptacosa-7,13,15,17,19-pentaene-24-carboxylic acid Chemical compound CC[C@H]1\C=C/C=C\C=C/C=C\[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@@H](O)C\C=C/C(=O)O[C@@H]1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O DVWJFTGEISXVSH-CWVFEVJCSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VCWMRQDBPZKXKG-UHFFFAOYSA-N (2S)-O1-alpha-D-Galactopyranosyl-myo-inosit Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(O)C1O VCWMRQDBPZKXKG-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- NXGJWKRNZOULRN-UHFFFAOYSA-N 1-(hydroxymethyl)-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(CO)C(=O)C2=C1N=CN2C NXGJWKRNZOULRN-UHFFFAOYSA-N 0.000 description 1
- 210000002925 A-like Anatomy 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- VCWMRQDBPZKXKG-FOHCLANXSA-N Galactinol Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)C1[C@@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O VCWMRQDBPZKXKG-FOHCLANXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- VCWMRQDBPZKXKG-DXNLKLAMSA-N alpha-D-galactosyl-(1->3)-1D-myo-inositol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@@H]1O VCWMRQDBPZKXKG-DXNLKLAMSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002086 anti-sebum Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000010635 coffee oil Substances 0.000 description 1
- 238000004939 coking Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003581 cosmetic carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229930193887 galanol Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008833 migu Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960000990 monobenzone Drugs 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical class CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 229930183279 tetramycin Natural products 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
Description
457094 A7 B7 經濟部中央標隼局員工消费合作社印製 4 五、發明説明( 本申叫案A共同申請中之美國專利序號08/712 988案的 邵份延續,其内容在此併入本文參考文獻。 本發明係、有關於-種適用於増加皮膚脂類合成之局部施 用·,合物。更明確地説,本發明係有關於一種包含咖啡醇 作爲脂類障壁促進物之組合物。 發明背景 以特徵而言,皮膚通常包含不同的三層,分別爲角質 層、表皮及眞丨。最外層之角質層係由角化細胞所形成, 周園細胞間隙由脂類所填充,角質層提供一堅固的生理障 土以避免沣义物免穿透皮膚下層。除了預防物質穿過其它 皮膚層外,此障壁亦能幫助防止水份由皮膚損失。這^樣 功忐基本上應歸功於角質層中所存在的脂類3 構成此重要障壁之皮膚表層脂類來源有二:皮脂腺及表 皮這些爿曰類爲一群各種不同之化合物,包括三酸甘油 酯、甘油二酯〈神經醯胺、游離脂肪酸、蠟酯、膽固醇及 膽固醇酯 '及鼓鯊烯。皮膚表面脂類之量及組成依身體部 位不同而異,且可能與特定皮膚區域之皮脂腺數目有某些 關係。皮膚表面脂類狀況亦可能受必需脂肪酸缺乏之影 響。除此之外’脂類障壁極易因暴露於剌激之清潔劑或肥 包而減少。因此’顯而易見的,皮膚脂類障壁之品質會因 许多不同因素而產生很大的變化,結果即可能無法始終產 生適當的保護功能。 本紙張尺度適用中國國家標準((:奶)八4規格(2丨0\297公1) .11 J n .~ 1 ~1 n H 訂 *~~11. I~~ - · 1 《請先閱讀背面之注意事項再填寫本頁} 457094 A7 B7 2 五、發明説明( 爲嘗試補償不足之脂類障壁’美容用组合物經常加入可 補償水份流失的成份。此類物質的實例有吸濕性潤濕劑, 如尿素或丙二醇:或潤滑劑’如油醇或三辛酸甘油酯/三 癸酸甘油酯。某些美容用品成份爲吸著性皮膚調養劑,能 提供一種”人工,,障壁:此類化合物爲常見的留在皮膚表面 之脂類,包括各種氫化油、壞及奶油。雖然許多此類產品 可提供有效防止皮膚水份流失的方法,但卻必_須經常重覆 使用以維持其功效,且通常無法組成-角質層天然產生的成 份,因此可能造成不自然的皮膚油腻感3除此之外,.各種 藥學或美容活性劑亦經常用於治療與皮膚乾燥病況相關的 症狀。然而於许多病例中’特別是使用藥劑時’治療本身 可能對被治療者造成不欲之副作用,而最終又無法實際修 復脂類障壁= 本發明現提供一種每日使用的皮膚調養劑或剌激局部活 性劑之有效替代品,目前已發現確實可能增強皮膚天然脂 類障壁的產生。明確的説,已發現當在皮膚上局部使用咖 啡醇時’可刺激產生一或多種天然產生之角質層脂類成 分’就如同增加角質層本身一般。結果提供一新型之美容 或藥學組合物,其功能爲增強皮膚本身功能,提供一較天 然的方法來預防乾燥皮膚及其他缺乏脂類障壁所導致之不 欲之結果= m B mjK_ 圖1爲一張薄層色譜(T L C )板照片’其顯示施用咖啡醇乙 酸酯於活组織皮膚模式之劑量-改變(左侧)及時間改變(右 ------- 5 -__ ___________ 本紙張级適用中_國家標準(CNS )八4綠(210X297公袭) ----------裝------,玎------Λ 1 < - (請先閱讀背面之注意事項再續容本百) 經濟部中央標準局貝工消費合作社印製 457五'發明説明(3 A7 B7 經濟部中央橾準局貝工消費合作社印製 側)的結果。每一項均顯示隨劑量及時間增加可増加神經醯 胺產量。 圖2也是-張薄層色譜板照片,依據劑量所増如神經酿胺 之產量來顯示施用咖啡醇乙酸酯與咖啡豆油於活组織皮膚 模式之比較結果。 . 圖3係以圖表顯示光密度分析法分析圖2所示之薄層色譜 板,其顯示以不同劑量治療時,皮膚中相對之神經醯胺: 量。 圖4係以圖表顯示使用咖啡醇乙酸酯及咖啡醇棕櫚酸酯於 障壁強度之效果:利用膠帶剝離法及TE (經表皮流失 水 ’ Transepidermal Water Loss)來測量 3 圖5係以圖表顯示使用咖啡醇於皮膚一段時間使產生神經 醯胺之效果。 * 圖6係依據劑量所增加神經醯胺產量,以圖表來顯示施用 咖啡醇於皮膚之相對效果。 發明摘要 本發明係有關於—局部組合物,包含做爲活性成份之有 效量的咖啡醇、咖啡豆醇或其衍生物,混以美容或藥學上 可接受之載劑。本發明亦係有關於一增加皮膚脂類合成之 方法,其包含施用有效量之咖噼醇或咖啡豆醇、或其衍生 物s由於脂類障壁係維持丰膚樣品及濕度的主要因子,因 此2部施用咖啡醇或其衍生物有益於增進整體皮膚狀態, 通#可預防或治療各種皮膚乾燥及因自然脂類障壁未完全 發揮作用或缺乏所引至之特殊皮膚狀況。 ----------裝-- r - (請先閲讀背面之注$項再填寫本頁)
k1T ^---------- i cns ) )
.In I 經濟部中央標準局員工消費合作社印裝 457094 A7 B7 -------*---- -----—----- 五、發明説明(4 ) 發明詳述 咖啡醇及咖啡豆醇,及/或其酯類爲咖啡豆油之二萜酯 (diterpene ester)部份的主要成份。咖啡醇之化學式如下:
市售醋化型商品有咖#醇乙酸酯。—.此類似結構咖啡豆醇 之化學式如下:
咖啡醇及其湘關化合物擁有多種不同的生物活性。如咖 啡豆油含有咖啡醇及咖啡豆醇,據稱爲有效的防曬劑(見於 美國專·利第4,793,990號)。咖啡精油之抽出物已與其他成 份,包括可可奶油及抗氧化劑,一起運用於香皂組合物: 該成份據稱可利用交互協同作用提供皮膚一層"單分予薄膜 ”(見於SU專利第1770352號)。另外.,咖啡醇本身與咖啡 豆醇合用於動物時,被認爲有對抗致癌物的保護作用{米 勒(MUler)等人 ’ Nutr. Cancer JJ_ : 41-46,1991 :哈給 (Huggett)與徐有特(Schilter),通俗國際咖啡科學c〇n〇q Sei· Int· Cafe[C‘R.] 14(1) : 65-72, 199-5 }。飲用大量未過 /慮咖啡的人之血清脂類濃度的增加亦與咖啡醇與咖啡豆醇 T"二…一 __-_ -7- 本紙張从適财g巧^準(CNS )八4胁(2丨0\297公釐) " ---- ----------种衣------ΪΤ------I (讀先閲讀背面之注意事項再.填寫本頁) 45709s 經濟部中央標準局員工消費合作社印製 A7 ____B7_五、發明说明(5 ) 有關[爾格特(Ui.gei‘t)等人,美國臨床營養週刊(Am.·】 Clin. Nutr.) ’ 第 61 卷,149 - i54 頁,1995 年]。 雖然直至目别爲止尚未確I忍,然而將咖啡醇或伽啡豆醇 單獨或併用直接施用於皮膚時,會有明顯剌激角質層脂類 生產的生物活性。結果出現了一種未預期的觀察現象,即 施用少量咖啡醇或咖啡豆醇於活組織皮膚模型可造成一明 顯、隨劑量加強而增加之多種重要角質層脂類。除此之 外,重覆施用單一劑量數日後可發現·神經醯胺的量随時間 延長而增加。治療後皮膚之組織學樣本顯示於治療後可測 知角質層之增加,表示此治療可促進眞皮層細胞的分化爲 角質層;這種具特異分化性的神經醯胺之增加在同樣的條 件之下皆爲固定的a明確的說,當咖啡豆油單獨使用於同 —療養過程時,效果確定。於臨床研究亦經由觀察經治療 測試者之神經醒胺的增加而證實這些結果,且更進—步經 治療測試者之障壁強度之增加來證實。 .由於具此活性之故,咖啡醇或咖啡豆醇爲非常有效之美 莩及/或局部使用之藥學组合物。用於本專利說明書及申 請專利範圍中,所謂,,有效量詞係指與同部位未治療皮 膚比較時能增加至少一種脂類障壁成份丨%湮生的劑量。 較佳爲至少增加一種脂類至少5%。或者’咖啡醇的藥效也 可藉由測量經表皮水流失琴示其強化脂類障壁之能力來評 估。在本文中’咖啡醇或咖啡豆醇之有效劑量係指其能增 加*員障壁至少5 %之強度,較佳爲於治療至少5天後增加 至少1 0 %。爲調配這樣的組合物,咖啡醇或咖啡豆醇之合 -~- -8- ---------批衣------ΪΤ------Λ (請先κ讀背面之注$項再填寫本育) 冬紙張尺度通灼1冢標準(CNS )六4規格(21〇χ297公釐) 457034 A7 B7 經濟部中央標準局負工消費合作社印裝 五、發明説明(6 併劑量佔本組合物由約每毫升0‘001至5〇毫克,較佳爲約 每毫升0.005至10.0毫克,更佳爲約每毫升〇〇1至ι〇毫 克,最佳爲每毫升Ο.!至丨毫克。請明瞭於本專利說明及申 請專利範圍中所指之”咖啡醇,,或"咖啡豆醇,,包括游離之咖 料或伽啡豆醇及任何其他安全,有效之衍生物,同型 物、或這些化合物之前驅物質,特別是它們的酯類’如: 乙酸酯、雙乙酸酯、棕櫚酸酯、亞麻油酸酯、硬脂酸酯、 =十虼酸酯、十四烷酸酯、二十二烷酸酯及二十四烷酸 酯、甲笨磺酸咖啡醇酯及1617無水咖啡醇或任何其混合 物。上述物質中許多係天然咖啡豆油中之成份’雖然其濃 度不而。活性成份最好具相當的純度,如至少純度7 〇 %, 較佳爲至少8 0 %且更佳爲9 0 %。 於局部使用時,咖啡醇或咖啡豆醇可與其他各種美容及 /或藥學上可接受之載劑合用。所謂"藥學上或美容可接受 之裁劑’,係指運用於藥學或美容之賦形劑,可傳遞活性成份 土所欲目標且不會傷害人類或其他接受治療的生物。請明 瞭在此所用"藥學上”或”美容,,—詞同時包括人類及動物用 策及美谷用品。實用的載劑包括,如水、丙酮、乙醇、乙 二醇、丙二醇、丨,3 _ 丁二醇、異丙基十四烷酸酯、異丙基 棕櫚酸酯、或礦物油。美容及藥學组合物的製造法及配方 成份爲眾所周知且可查詢的,如:於雷明頓醫藥科學 (Remington's Pharmaceutical Sciences),第 18版,A.R·簡 纳洛(A.R. Gennaro)編’馬克出版公今(Mack Publishing C 〇,)’ 東賓州(Easton Pennsylvania),1990年。載劑可爲 衣纸張尺度it用中国國家標準(CNS ) A4規格(210X297公釐) ----------^------1T------ ' -- (請先聞讀背面之注意事項再填寫本頁) 457094 Α7 Β7 五 經濟部中央標準局員工消費合作社印製 、發明説明( 通。傳遞方式之任何型式。如:溶劑 '膠態分散劑、乳劑 (水中油或油中水)、懸浮劑、膏劑、洗劑、膠劑、泡沐 劑、慕絲、噴劑及類似物3 本配方除載劑及活性雙萜成份外,亦可包含其它成份, 其可依载劑與/或欲使用的配方來選擇。添加成份包括(但 不限於)水溶性染料(如F D & c藍色丨號):油溶性染料(如 D&C綠色6號)、水溶性防曬劑[如:優收雷克斯 、油溶性防曬劑(如:辛基甲氧.基肉桂酸鹽)、特化防 別(如:氧化鋅)、抗氧化劑(如:Β Η τ )、螯合劑(如二納 Α)乳狀妓·夂劑[如:卡爾玻抹(carbomer)]、防腐劑 [如.甲基帕拉本(paraben)]、香料(如··苹晞)、調味劑 (如·山黎糖醇)、濕潤劑(如:甘油)、防水劑(如:P V P / 二十碳烯共聚物)、水溶性成膜劑(如:羥丙基甲基纖維 素)、油溶性成膜劑(如:氫化c_9樹脂)、陽離子聚合物 [如.枭夸特尼恩〗〇(p〇Iyquaternium 1〇)]、陰離子聚合物 [如•黃酸樹膠(xanthan gum)]、維生素(如:維生素£)及 類似物。 本組合物之治療/美容用途極廣,可治療或預防任何皮 膚天然脂類障壁有風險、缺陷或受損之情況。如含咖啡醇· 或咖啡豆醇-之纽合物可用於預防或治療—般皮膚乾燥之狀 沉’或特殊之皮膚乾燥狀況,如經常暴露於清潔劑、肥包 及熱水之中:季節性暴露於惡劣氣候狀況,如寒冷 '多風 及/或陽光下:職業性暴露於剌激化學品或其它乾 傷害性物質中:或病理狀況如濕疹性皮膚炎、乾癖、魚鱗 -10- 本紙張尺度適用中國國家標準(CNS ) A4说格(210X297公楚) 經濟部中央標準局貝工消費合作社印裝 457094 A7 ____ B7 五、發明説明(8 ) #、乾燥症及其類似症狀。眾所周知的乾燥皮膚也常與老 化(内在與光老化)有關,而咖啡醇/咖啡豆醇組合物可用 於預防更進一步對老化皮膚的傷害,或治療及/或反轉已 出現之傷菩。本组合物亦可用於治療有缺陷之皮膚障壁, 如發生於腳底、手掌之角質層肥厚,但脂類障壁缺乏的情 形。除此之外,有缺陷之皮膚障壁經常發生於燒傷、創 傷、水泡、鬱滯性潰瘍及褥瘡:類似之傷害可-經由施用本 發明之组合物而改善。本组合物亦有..益於增強皮膚用藥之 傳遞。 由先前所列本組合物之相關申請案之説明可知,本組合 物亦有益於與其他使用於皮膚治療(美容上及藥學上)、或 例行局都施用的活性劑結合使用。這些可有效與咖啡醇或 咖啡豆醇合用的活性劑實例包括(但不限於)一些可改善或 去除老人斑、角化及皺紋、止痛劑、麻醉劑、抗粉剌劑、 抗菌劑、抗酵母劑、抗擻菌劑 '抗病毒劑、去頭皮屑劑' 抗皮炎劑、止癢劑、止吐劑、暈車藥、消炎劑、抗角化過 度劑、抗皮膚乾燥劑、止汗劑、止癬劑、抗皮脂漏劑、護 髮劑及毛整調理劑、抗老化劑、抗皺纹劑、止喘劑及氣管 擴張劑、防曬劑、抗阻織胺劑、皮膚淡化劑、去色素劑、 傷口癒合劑、維生素、類固醇、黑膚劑、或荷爾蒙。其他 更明確的有效活性劑實例包括類維他命A物質、局部心血 f劑、可婁去馬吐(clotrimazole)、克康那唑 (ketoconazole)、麥康那咕(miconozo丨_e) '灰黃徵素、氫 氧仁(hydroxyzine)、二苯氫胺(diphenhydramine)、普拉 _______ - 11 -_______ 本紙張尺度適用中國國家標準(CNS ) A4規格(2IOX297公变) ---------^------.玎------A (請先閲請背面之注意事項再填寫本頁) 5 4 η 經濟部宁央標準局員工消費合作社印褽 Α7 Β7 五、發明説明(9 ) 模新(pramoxine)、利多卡因、普羅卡因、牧皮娃卡因 (mepivacaine)、單笨銅(monobenzone)、紅徵素、四 $衣黴 素、氣林絲菌素(clindamycin)、枚可婁赛林 (meclocyline)、氩酿(hydroquinone)、米諸;衣微素 (minocycline)、那普洛辛(naproxen)、異布洛务 (ibuprofen)、茶給·、可羅莫林(cromolyn),歐布特醇 (albuterol)、類維生素 A酸(retinoic acid)、13-順類維生 素A酸(13-cis retinoic acid)、氫皮質酮、氫皮質酮21·乙 酸酯、氫皮質酮1 7 -戍酸酯、氫皮質酮1 7 - 丁酸酯、貝它美 松(betamethasone)戊酸酯、貝它美松二丙酸酯 (betamethasone diproprionate)、DHEA及其衍生物.、三安 西错隆丙明化物(triamcinolone acetonide)、氯西諾耐 (fluocinonide)、克婁貝他蒐(clobetasol)、丙酸酯 (proprionate)、 過氧化笨甲醯、克羅他密頓 (crotamiton)、晋潘奈(pr〇pran〇i〇i)、普美苯違 _ (promethazine) '維生素a棕搁酸酯、維生素E乙酸酯及其 處合物。使用於任何配方中的活性劑劑量與一般使用劑量 相同3 本组合物之應用方法及使用頻率依组合物型式及須治療 或預防之狀况本質不同而異。關於施用方法,利用.一般使 用同類型组合物的方法來施用本组合物,如使用藥膏或洗劑 來濕潤皮膚。至於頻率則依治療現有之皮膚乾造狀況或其 他與缺損、受傷害、或缺乏障壁有關冬狀況來使用本組合 物,如,視情況所需使用至病況改善,或當經常暴露於會 ---------「裝------訂------A (請先閱讀背面之注意事項再填寫本頁〕 - 12 私紙張尺度通用中國國家標準(CNS ) M祕(训幻97公货 457094 經濟部中央標準局員工消費合作社印黎 A7 B7 五、發明説明(11 )
Bioscan)進行TLC板之光密度分析。 C.组織學。爲測量施用咖啡醇於活組織皮膚之组織學上 的作用’將皮膚塊依上述方式處理後,於培養期結束後將 樣衣固定、切片、並用蘇木紫/伊紅染色。 II. 活組織皮膚模式-結果 以二批活組織皮膚進行依劑量爲基準之實驗。二组實驗 之HPTLC均明確顯示能依劑量造成神經醯胺選擇性的増 加。同樣的’依時間爲基準之實驗亦.明確顯示僅施用一日 後神經醯胺即出現’且於施用三曰後達最高濃度(圖丨)。 咖啡豆油脂之比較實驗證實了最初的結果,顯示於以咖 啡醇處理的皮膚可隨劑量而增加神經醯胺的產量(圓2)。 T L C板之光备度分析掃描顯示與此發現同樣的模式。然 而’含咖啡醇乙酸酯之咖啡豆油顯示僅能增加少許的神經 S鱼胺(圖3 )-’處理過樣本之組織學分析顯示角質層明顯増 加’表示其確實可引起角質層之分化,藉由神經醯胺的増 加(已知具分化特異性)也進一步證實這項假説。 III. 人類皮膚臨床研究-材料及方法 A .測定咖啡醇對脂類產生之活性,首先試驗單一個體顯 示當咖啡醇直接施用於皮膚三天後,神經醯胺I含量上升。 隨後於同樣條件下進行一個有五位受試者之短期臨床崎 究’以測試咖啡醇乙酸酯項加神經醯胺濃度之能力。首先 以乙醇洗滌以移除雙二臂之角質層脂類。製備含咖啡醇乙 酸酯濃度每毫升1毫克之乙醇,每曰二_次以幫浦噴灑於右 前臂内側。控制組則使用乙醇於左臂之相對位置。第三 ____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ~ - . i 訂 . -I— n .·4 (請先閲讀背面之注意事項^^寫本頁> 457094 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(12 ) 天’再度移除角質層脂類且將雙臂之初始及第三天之脂類 如上述方法以薄膜色譜法測量, B.如啡醇對皮膚障壁功能之效用。十名年齡於25_45歲 間的健康女性受試者’於此研究中將以她們正常的前臂皮 膚來做測試。受試者於試驗當天並未使用任何治療或美容 化妝產品。於基礎測量記錄前使她們適應相對濕度4 〇 %及 7 0 F的室内環境2 〇分鐘。隨後任意分配爲二治療群组a 第I組(η = 5)接受之治療爲在—手臂上使用含〇1〇/〇咖啡 醇,而另一臂則用安慰劑a第U組(η + 5 )在—手臂上使用 含〇. 2 %咖啡醇標櫚酸酯,且以含〇. 1 %咖味醇乙酸跪於另 —臂。除了測量當天外,受試者每曰兩次自己處理掌側前 臂下側。 在前臂下内側以模板標出一5 X 2公分平方的區域並首先 以水蒸發法測量每行3個間隔1公分的獨立點。將5公分長 的纖維膠帶置於標出的皮膚區,從兩個方向各用力塾一下 後,由頂端開始以與皮膚平行的方向輕輕拉下。重複此步 驟並每累積5至1 〇片後進行水蒸發法測量,直到障壁破損 爲止,即二點中的一點之最小水蒸氣壓達到每小時每平方 公尺1 8公克爲止。監測受試者測試部位經過丨,2及3天後 的經表皮流失水(TEWL)以測量皮膚的修復能力^經過5至 1 0天的產品處理後’於相[司情況下在鄰近的新部位重複上 述程序。 以燈罩及網連接色磨醫學蒸氣量計(Serv〇 Med Evapodmeter)測量TEWL 3受試者以放鬆彎身姿勢’並不 -----_广 1^— (请先閲讀背面之注意事項再續寫本育) .裝' 訂 泉 本紙張又度適用中國國家標準(CNS )八4規格(2丨0X297公釐) 經濟部中央標準局員工消費合作社中製 457094 A7 _' _B7 五、發明説明(13 ) 許談話或變興奮。利用代爾-史創(Dia-Stron)電腦程式(設 定爲獲得3 0秒資料及I 5秒高原期)來自動記錄TEWL。 I V _臨床研究人類皮膚·結果 A .測量人類皮膚之神經醯胺濃度。薄膜色譜法顯示接受 咖啡醇治療五名受試者中有四名手臂之神經醯胺I濃度增 加,儘管每名試驗者之效力不同。除此之外,該名神經醯 胺I未增加之受試者顯示了神經酿胺I v的增加。- β ·障壁強度測量。藉由膠帶剝離測·試皮膚及測量水份蒸 發(water evaporation, WE)來評估障壁強度。爲描述實驗 數據’根據最小方塊法(least-square )以曲線配合線性回歸 (curve fitting Linear Regression)分析每次每—個體數據 及達成每小時每平方公尺1 8公克W E所需膠帶剥離的數 目。擾亂障壁所需膠帶剝離的數目即可測量其強度。 根據該評估結果,使用咖啡醇乙酸醋之試驗組顯示於治 療5及10天後其障壁強度增加10%及38%,使用咖啡醇棕 櫚酸酯之試驗组則顯示其障壁強度增加8 %及4 3 %,使用安 慰劑之試驗組則顯示其障壁強度增加3 %及7%。圖4概述這 些結果。 觀察剝離邵位之修復速率三天。記綠起始及治療後5及 1 0天之T E W L增加及剥離部位恢復比例。 這些結果並未顯示治療#障壁修復效率有任何影響。 16 - 各紙張又度適用中國國家標準(CNS ) A4規格(210X297公釐) ----------^------ir------^ - -, (请先閲讀背面之注意事項再楨寫本頁) ^57...0.94 气4沪1奢正 _補充 第86113282號專利申請案 中文補充說明書(90年4月] 咖啡豆醇增進皮膚障壁合滅之試.驗乃數據 方法:活組織皮膚模型(epi2O0)由MatTek公司取得,以增加81°/。純咖啡醇/ 咖啡豆醇含量之混合物處理。此組織培養物每日再加入此混合物直至三 天。此外,亦有未經處理的對照組及經咖啡醇乙酸酯(sigma)處理之樣本。 該樣本經均質化後以氯仿/甲醇(2:1)萃取,再取出i毫升的氯仿萃取物並乾 燥。此樣本隨後經再懸浮後以HPLC進行層析。在TLC板的樣本經酸降解 焦化法可見化後’以影像分析測定其個別的淨強度。 結果:下列係自HPTLC板的樣本測量神經醯胺在脂質萃取物中的淨強度。 表1 :神經醯胺的增加 濃度(毫克/毫升) 淨強度(1〇3) 控制組 0 21.4 咖啡醇 0.10 40.0 C/K(咖啡醇/咖啡豆醇) 0.05 39.2 C/K 0.10 35.2 C/K 0.50 18.3 由表1可知,咖啡醇濃度細毫統升及c/κ濃度在0.05及(Μ毫克/毫 升時’神經酿胺(Cer)增加。然而,C/K濃度在〇_5毫克/毫升時此增加情形 消失’但另-種神經酿胺(NCer)則伴隨地增加,其與復劑量有關。
PAWlCC\CHINES&495V3SUPD〇C 4 5 7 0 9 4 表2 :新神經酿胺的增加 濃度(毫克/毫升) -一 *" 淨強度(103) 控制組 0 11.0 咖啡醇 0.10 11.1 c/κ(咖啡醇/咖啡豆醇) 0.05 33.3 C/K 0.10 41.3 C/K 0.50 52.6 此結果顯示,含有咖啡豆醇的组合物,甚至在最低使用濃度(〇〇5亳克/毫升) 因結果顯袖啡豆醇在較高劑量轉鰣加此種神 可知咖啡頭亦具有增域麟私成之能力。 B寺亦可在活皮膚模财增加神經酿胺含量^此外,亦可測得另—種與沉 劑量相關的神經酿胺 ’ 經醯胺累積的角色,
P:\WKC\CHINESE\49513SUP D0C I -2 -
Claims (1)
- 5 7 0 久 ' 年 Hj282號專利申請案 f 專利範圍修正本(9〇年4月) 申請專利範圍經濟部中央標準局負工消费合作社印裝 L —種用於增加皮膚脂類障壁合成之局部組合物其包含 作為活性成份之有效量咖啡醇或咖啡豆醇,或其組合 物’與美容上或藥學上可接受之載劑組合。 2.根據申請專利範圍第1項之局部組合物,其包含咖啡醇或 咖啡豆醇酯。 3·根據申請專利範圍第2項之局部組合物,其中醋類為乙酸 酯、棕櫚酸酯、亞麻油酸酯、硬脂酸酯或二十烷酸酯。 4. 根據申請專利範圍第丨項之局部組合物,其包含咖啡醇。 5. 根據申請專利範圍第丨項之局部組合物,其包含咖啡豆 醇。 6. 根據申請專利範圍第]項之局部组合物,其同時包含咖啡 醇及咖豆醇。 7. 根據申請專利範圍第丨項之局部組合物,其中咖啡醇或咖 啡且醇之有效量為每毫升約〇·〇〇1至約5〇毫克。 8_根據申請專利範圍第丨項之局部組合物,其中咖啡醇或咖 啡豆醇之有效量為每毫升約0 005至約1〇 〇毫克。 9_根據申請專利範圍第1項之局部組合物,其中咖啡醇或咖 啡豆醇之有效量為每毫升約〇 _ 〇丨至約丨〇毫克。 10. 根據申請專利範圍第1項之局部組合物,其中之脂類為神 經醯胺。 11. 根據申請專利範圍第10項之局部組合物,其中之脂類為 神經醯胺I或神經醯胺IV。 12. 根據申請專利範圍第1項之局部組合物,當施用於皮廣時 用於改進皮膚狀態。 本紙張尺度適用尹國國家揉準(CNS ) A4洗格(2丨0X297公釐) ----------參------1T------^ (请先聞讀背面之注意事項再蜞寫本頁) 457094 ABCD 六、申請專利範圍 13. 根據申請專利範圍第1項之局部組合物,當施用於皮膺時 用於治療或促進乾燥皮膚狀態。 14. 根據申請專利範圍第1項之局部組合物,當施用於皮膚時 用於治療與脂類障壁缺陷或減少有關之皮膚狀態。 15. 根據申請專利範圍第1項之局部組合物,當施用於皮膚時 用於増強皮膚脂類障壁。 (請先閲讀背面之注意ί項再填寫本頁) 經濟部中央橾準局貝工消費合作社印製 本紙張尺度適用t國國家揉準(CNS ) Α4規格(2丨0Χ297公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/712,988 US5855897A (en) | 1996-09-13 | 1996-09-13 | Topical composition and method for enhancing lipid barrier synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW457094B true TW457094B (en) | 2001-10-01 |
Family
ID=24864332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW086113282A TW457094B (en) | 1996-09-13 | 1997-09-12 | Topical composition for enhancing lipid barrier synthesis |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5855897A (zh) |
| EP (1) | EP0955993B1 (zh) |
| JP (2) | JP2001500131A (zh) |
| KR (1) | KR100519638B1 (zh) |
| AR (1) | AR008632A1 (zh) |
| AT (1) | ATE303125T1 (zh) |
| AU (1) | AU727993B2 (zh) |
| CA (1) | CA2266048C (zh) |
| CO (1) | CO4900022A1 (zh) |
| DE (1) | DE69734114T2 (zh) |
| ES (1) | ES2248855T3 (zh) |
| TW (1) | TW457094B (zh) |
| WO (1) | WO1998010739A1 (zh) |
| ZA (1) | ZA978235B (zh) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716437B1 (en) | 1993-09-13 | 2004-04-06 | E-L Management Corporation | Topical composition and method for enhancing lipid barrier synthesis |
| US7204848B1 (en) * | 1995-03-01 | 2007-04-17 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
| DE19824727A1 (de) * | 1998-06-03 | 1999-12-09 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Catechinen oder einem Gehalt an Extrakt von grünem Tee |
| US6515029B1 (en) | 1999-04-23 | 2003-02-04 | Kimberly-Clark Worldwide, Inc. | Absorbent article having a hydrophilic lotionized bodyside liner |
| US7141062B1 (en) * | 2000-03-01 | 2006-11-28 | Medinol, Ltd. | Longitudinally flexible stent |
| FR2811563B1 (fr) * | 2000-07-13 | 2003-06-20 | Oreal | Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive, et au moins un compose augmentant la synthese des glycosaminoglycanes |
| FR2811561B1 (fr) * | 2000-07-13 | 2003-03-21 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase |
| US6756520B1 (en) | 2000-10-20 | 2004-06-29 | Kimberly-Clark Worldwide, Inc. | Hydrophilic compositions for use on absorbent articles to enhance skin barrier |
| US6503526B1 (en) | 2000-10-20 | 2003-01-07 | Kimberly-Clark Worldwide, Inc. | Absorbent articles enhancing skin barrier function |
| US20020120241A1 (en) * | 2000-12-22 | 2002-08-29 | Tyrrell David John | Absorbent articles with hydrophilic compositions containing anionic polymers |
| US20020120242A1 (en) * | 2000-12-22 | 2002-08-29 | Tyrrell David John | Absorbent articles with hydrophilic compositions containing botanicals |
| US20020128615A1 (en) | 2000-12-22 | 2002-09-12 | Tyrrell David John | Absorbent articles with non-aqueous compositions containing anionic polymers |
| US7771735B2 (en) * | 2000-12-22 | 2010-08-10 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with compositions for reducing irritation response |
| US6749860B2 (en) | 2000-12-22 | 2004-06-15 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with non-aqueous compositions containing botanicals |
| US20030130636A1 (en) * | 2001-12-22 | 2003-07-10 | Brock Earl David | System for improving skin health of absorbent article wearers |
| US7354956B2 (en) * | 2002-04-12 | 2008-04-08 | L'oreal | Composition containing a sapogenin and use thereof |
| WO2004103334A1 (en) * | 2003-05-20 | 2004-12-02 | Sederma | Slimming cosmetic composition comprising cafestol or kahweol |
| FR2855057B1 (fr) * | 2003-05-20 | 2006-07-14 | Sederma Sa | Composition cosmetique ou dermopharmaceutique amincissante |
| US20060177392A1 (en) * | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
| DE102006008772A1 (de) * | 2006-02-22 | 2007-08-23 | Beiersdorf Ag | Hydroxymatairesinol gegen trockene Haut |
| WO2015036892A1 (en) * | 2013-09-12 | 2015-03-19 | Pfizer Inc. | Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris |
| CN106573063A (zh) | 2014-05-30 | 2017-04-19 | 奥尔胡斯大学 | 用于治疗糖尿病的咖啡醇 |
| US20220267380A1 (en) | 2019-07-17 | 2022-08-25 | Tfchem | Glycopeptides Increasing Lipid Synthesis |
| WO2022157233A1 (en) | 2021-01-20 | 2022-07-28 | Tfchem | Cyclic glycoaminoacid derivatives |
| CN113648303B (zh) * | 2021-08-20 | 2022-12-20 | 中山大学 | 咖啡醇或其衍生物在制备抗白色念珠菌药物或抗白色念珠菌日用品中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU82323A1 (fr) * | 1980-04-02 | 1981-12-02 | Oreal | Utilisation de l'huile de cafe comme agent filtrant solair,composition et procede de protection la mettant en oeuvre |
| US4748258A (en) * | 1986-04-03 | 1988-05-31 | Nestec S.A. | Preparation of a mixture of cafestol and kahweol |
| RU1770352C (ru) * | 1991-01-08 | 1992-10-23 | Научно-производственное объединение "Аэрозоль" | Туалетное мыло |
-
1996
- 1996-09-13 US US08/712,988 patent/US5855897A/en not_active Expired - Fee Related
-
1997
- 1997-09-11 AT AT97943321T patent/ATE303125T1/de not_active IP Right Cessation
- 1997-09-11 CA CA002266048A patent/CA2266048C/en not_active Expired - Fee Related
- 1997-09-11 AU AU44818/97A patent/AU727993B2/en not_active Ceased
- 1997-09-11 JP JP10513039A patent/JP2001500131A/ja active Pending
- 1997-09-11 KR KR10-1999-7001993A patent/KR100519638B1/ko not_active Expired - Fee Related
- 1997-09-11 ES ES97943321T patent/ES2248855T3/es not_active Expired - Lifetime
- 1997-09-11 EP EP97943321A patent/EP0955993B1/en not_active Expired - Lifetime
- 1997-09-11 WO PCT/US1997/016364 patent/WO1998010739A1/en not_active Ceased
- 1997-09-11 DE DE69734114T patent/DE69734114T2/de not_active Expired - Fee Related
- 1997-09-12 AR ARP970104200A patent/AR008632A1/es unknown
- 1997-09-12 TW TW086113282A patent/TW457094B/zh not_active IP Right Cessation
- 1997-09-12 CO CO97053296A patent/CO4900022A1/es unknown
- 1997-09-12 ZA ZA9708235A patent/ZA978235B/xx unknown
-
2006
- 2006-03-01 JP JP2006055031A patent/JP2006193530A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2266048C (en) | 2007-07-03 |
| US5855897A (en) | 1999-01-05 |
| ES2248855T3 (es) | 2006-03-16 |
| DE69734114T2 (de) | 2006-10-19 |
| DE69734114D1 (de) | 2005-10-06 |
| WO1998010739A1 (en) | 1998-03-19 |
| CA2266048A1 (en) | 1998-03-19 |
| ZA978235B (en) | 1998-03-03 |
| KR20000036019A (ko) | 2000-06-26 |
| AU4481897A (en) | 1998-04-02 |
| EP0955993A1 (en) | 1999-11-17 |
| EP0955993B1 (en) | 2005-08-31 |
| CO4900022A1 (es) | 2000-03-27 |
| JP2006193530A (ja) | 2006-07-27 |
| EP0955993A4 (en) | 2000-02-23 |
| AR008632A1 (es) | 2000-02-09 |
| ATE303125T1 (de) | 2005-09-15 |
| JP2001500131A (ja) | 2001-01-09 |
| KR100519638B1 (ko) | 2005-10-10 |
| AU727993B2 (en) | 2001-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW457094B (en) | Topical composition for enhancing lipid barrier synthesis | |
| US6468564B1 (en) | Topical compositions containing lotus for skin treatment | |
| US5616332A (en) | Cosmetic skin-renewal-stimulating composition with long-term irritation control | |
| EP0855904B1 (en) | Barrier disruption treatments for structurally deteriorated skin | |
| EP1732500B1 (en) | Cosmetic composition and method for retarding hair growth | |
| CN1663559B (zh) | 皮肤健全剂 | |
| Goldberg et al. | Clinical evidence of the efficacy and safety of a new 3‐in‐1 anti‐aging topical night serum‐in‐oil containing melatonin, bakuchiol, and ascorbyl tetraisopalmitate: 103 females treated from 28 to 84 days | |
| EA009006B1 (ru) | Способ обработки кожи и композиция для косметической обработки кожи | |
| WO2001017499A1 (en) | Skin normalizing agents | |
| JP2010520232A (ja) | 玄参抽出物を含有する外用剤組成物及びその皮膚保湿化粧料としての用途 | |
| EP1069883B1 (en) | Self-tanning compositions comprising cholesterol sulphate and DHA | |
| TW201412323A (zh) | 用於治療慢性發炎皮膚病之局部用組成物 | |
| CN103494737A (zh) | 一种以姜花作为抗衰老护肤因子的化妆品制剂及制备方法 | |
| Moglia et al. | Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses | |
| EP1214926B1 (en) | Topical composition | |
| KR102333132B1 (ko) | 프랜지패니 오일 또는 프랜지패니 오일의 발효물을 포함하는 화장료 조성물 | |
| JP2002128702A (ja) | 局所活性成分の効力のモノ−アシル−(リゾ)−グリセロリン脂質による増強方法およびその用途 | |
| US6716437B1 (en) | Topical composition and method for enhancing lipid barrier synthesis | |
| KR101615900B1 (ko) | 커큐마 잔소리자를 유효성분으로 함유하는 피부 노화 방지용 조성물 | |
| Maenthaisong et al. | Cleansing lotion containing tamarind fruit pulp extract. III. Study of lightening efficacy and skin irritation on Asian skin type | |
| EA039464B1 (ru) | Композиции для местного применения для ухода за кожей | |
| Lodén | Keratolytics | |
| CN101198377A (zh) | 含有至少一种噁唑啉作为活性组分的祛斑或美白用美容组合物 | |
| CN119792143A (zh) | 一种组合物及其应用 | |
| HK1033912B (zh) | 包含膽固醇硫酸鹽和二十二碳六烯酸的自用美黑合成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |